Latest news with #RaptTherapeutics
Yahoo
14-06-2025
- Business
- Yahoo
Rapt Therapeutics announces effective date for 1-for-8 reverse stock split
RAPT Therapeutics (RAPT) announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Global Market under the symbol 'RAPT' with the new CUSIP number 75382E 208. The Company's common stock will begin trading on a reverse stock split-adjusted basis on June 17, 2025. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on RAPT: Disclaimer & DisclosureReport an Issue RAPT Therapeutics Announces Development Plans for RPT904 Rapt Therapeutics started at Buy at Clear Street on RPT904b opportunity Rapt Therapeutics initiated with a Buy at Clear Street RAPT Therapeutics Faces Nasdaq Delisting Notice Rapt Therapeutics price target lowered to $1 from $2 at UBS Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
06-06-2025
- Business
- Business Insider
Rapt Therapeutics started at Buy at Clear Street on RPT904b opportunity
Clear Street initiated coverage of Rapt Therapeutics (RAPT) with a Buy rating and $3 price target. The firm's bullish call is driven by a strong conviction in RPT904b – a potentially best-in-class anti-IgE antibody for food allergy and chronic spontaneous urticaria that is comparable to Roche (RHHBY) and Novartis' (NVS) Xolair, the analyst tells investors in a research note. Rapt's 76% stock decline over 12 months relative to XBI's 12% is primarily attributable to an unrelated asset discontinuation and has created a 'significant opportunity', the firm added. Confident Investing Starts Here:
Business Insider
06-06-2025
- Business
- Business Insider
Rapt Therapeutics initiated with a Buy at Clear Street
Clear Street initiated coverage of Rapt Therapeutics (RAPT) with a Buy rating and $3 price target Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
